Merck licenses preclinical KRAS G12D(ON) inhibitor SPR2015 from SciBrunch

What happened

Merck (NYSE: MRK), known as MSD outside the United States and Canada, said on 28 September 2026 that it had signed an exclusive global license agreement with SciBrunch Therapeutics Co., Ltd. for SPR2015, an investigational oral KRAS G12D(ON) inhibitor ^[1]. The asset is preclinical: the announcement gives no clinical phase and no trial identifier ^[1].

That is the verifiable event in full. One line of substance, one of stage. In the field's shorthand, an (ON) inhibitor is built to engage the active, GTP-bound form of the mutant, a different chemical bet from the (OFF)-state inhibitors. Merck is buying early optionality on that approach, not a clinical contender.

Why it matters

For a team running a KRAS program, the useful read is how far this sits from mattering. Preclinical puts a first-in-human trial, if SPR2015 gets there, years out, and any efficacy signal further still. A large-cap paying to option active-state G12D chemistry at this stage reads as target validation more than as near-term competitive pressure.

The framing around the deal, that it extends a KRAS franchise or answers a race for the G12D active-state niche, is the announcement's own context, and Prognyx cannot independently source it here. Merck's existing G12C or G12D assets, SciBrunch's wider pipeline, and any rival G12D(ON) programs are absent from the public record retrieved for this briefing. Treat the franchise story as the seller's frame until a filing or a registered trial gives it shape.

The target has been unforgiving. Endpoints reported that Elicio Therapeutics' pancreatic cancer vaccine failed a Phase 2 study and that the company is still seeking Phase 3 funding ^[2]. Different modality, same lesson: KRAS validation and clinical success sit far apart, which is why a cheap preclinical bolt-on is the rational move for a buyer with Merck's balance sheet.

What to watch next

Merck attached no dates to any next step. The signals that would move this from a press line to a program are a first-in-human trial for SPR2015 appearing on ClinicalTrials.gov and any disclosure of financial terms (upfront, milestones, royalties) in Merck's next quarterly filing. Neither is scheduled in the public record retrieved here.

The now-what

• Clinical-stage KRAS developers: hold your timeline. A preclinical entrant from a large-cap strengthens the case for the target without touching your lead's position.
• Preclinical KRAS sellers: Merck is an active, paying acquirer for active-state G12D chemistry at the preclinical stage. That is a usable reference point for your own BD conversations.
• Partnering and BD teams tracking Merck: the undisclosed terms carry more information than the headline. Wait for the quarterly line before sizing what Merck paid to enter this niche.

What Prognyx could not verify

Deal economics (upfront, milestones, royalties) were not in any source retrieved. SciBrunch Therapeutics' independent identity and pipeline were available through Merck's release and its wire syndication, not a primary SciBrunch document. No SEC filing confirming the transaction and no trial record for SPR2015 were in the retrieved set; their absence here is not proof that they do not exist.

Verdict: threat level low, no forced window to act. A preclinical bolt-on that validates active-state G12D more than it pressures any clinical program; revisit when a trial registers or terms surface.